FluoroPharma, a developer of imaging agents used in association with positron emission tomography (PET) scanning, was founded in 2003 by Dr. David Elmaleh, currently the company's Chief Scientific Officer, who has gathered around him some of the most knowledgeable people in the radiopharmaceutical and medical technology industries. Together they are developing a protected portfolio of PET tracer agents, including their lead products, CardioPET, BFPET, and VasoPET, designed for use in evaluating different processes associated with coronary artery disease (NYSEARCA:CAD), the country's #1 killer. Nearly one-third of all Americans are believed to have some form of cardiovascular disease.
People with CAD typically have plaque accumulations on their coronary artery walls. As a result, their heart cells can end up getting a reduced supply of oxygen, which can eventually cause increasing chest pain and ultimately a heart attack. CAD is a progressive disease, and can lead to sudden death, with little or no warning. That's where cardiac imaging comes in. Using PET technology, with the specially designed tracer chemicals from FluoroPharma, doctors can detect regions of metabolic insufficiency and measure cardiovascular blood flow and inflamed plaque, giving them a vital lead in identifying heart disease before the first symptoms even appear.
Traditionally, for low to moderate risk patients, an exercise stress test was used to measure heart function, determining the heart's ability to respond to external stress. The patient is attached to an EKG monitor, while undergoing various levels of activity on a treadmill or stationary bicycle. However, such tests are known for their relatively low accuracy and poor reliability in evaluating the patient's risk of heart attack. And stress tests have no way of detecting what are called vulnerable plaques, which are plaques more likely to cause an attack. But someday soon the traditional stress test could go the way of the dinosaur. VasoPET in particular is being designed to identify such vulnerable plaques, providing a much earlier and more accurate CAD picture than any stress test. Together with the other FluoroPharma cardio related products, doctors will at last be able to gain a clear view of heart disease at its earliest stages, potentially saving lives and countering the huge social and economic costs associated with CAD.
For more information, see the company website at FluoroPharma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net